X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES GSK PHARMA SUVEN LIFESCIENCES/
GSK PHARMA
 
P/E (TTM) x 19.0 46.5 40.8% View Chart
P/BV x 3.7 9.2 40.1% View Chart
Dividend Yield % 0.6 1.7 35.9%  

Financials

 SUVEN LIFESCIENCES   GSK PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
GSK PHARMA
Mar-19
SUVEN LIFESCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2513,595 7.0%   
Low Rs1551,253 12.4%   
Sales per share (Unadj.) Rs49.1184.7 26.6%  
Earnings per share (Unadj.) Rs9.726.3 37.0%  
Cash flow per share (Unadj.) Rs11.429.2 39.1%  
Dividends per share (Unadj.) Rs1.5020.00 7.5%  
Dividend yield (eoy) %0.70.8 89.6%  
Book value per share (Unadj.) Rs60.3126.3 47.7%  
Shares outstanding (eoy) m127.28169.40 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.113.1 31.5%   
Avg P/E ratio x20.992.2 22.6%  
P/CF ratio (eoy) x17.883.1 21.4%  
Price / Book Value ratio x3.419.2 17.5%  
Dividend payout %15.476.1 20.3%   
Avg Mkt Cap Rs m25,825410,626 6.3%   
No. of employees `0001.15.0 21.6%   
Total wages/salary Rs m6135,372 11.4%   
Avg. sales/employee Rs Th5,832.66,306.7 92.5%   
Avg. wages/employee Rs Th571.51,083.1 52.8%   
Avg. net profit/employee Rs Th1,153.8898.0 128.5%   
INCOME DATA
Net Sales Rs m6,25331,281 20.0%  
Other income Rs m2331,023 22.7%   
Total revenues Rs m6,48532,304 20.1%   
Gross profit Rs m1,9826,009 33.0%  
Depreciation Rs m213486 43.8%   
Interest Rs m466 771.7%   
Profit before tax Rs m1,9556,540 29.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m7182,373 30.3%   
Profit after tax Rs m1,2374,454 27.8%  
Gross profit margin %31.719.2 165.0%  
Effective tax rate %36.736.3 101.2%   
Net profit margin %19.814.2 138.9%  
BALANCE SHEET DATA
Current assets Rs m5,62220,061 28.0%   
Current liabilities Rs m1,16814,543 8.0%   
Net working cap to sales %71.217.6 403.9%  
Current ratio x4.81.4 349.1%  
Inventory Days Days8157 143.4%  
Debtors Days Days3614 255.5%  
Net fixed assets Rs m3,32514,343 23.2%   
Share capital Rs m1271,694 7.5%   
"Free" reserves Rs m7,54719,704 38.3%   
Net worth Rs m7,67421,398 35.9%   
Long term debt Rs m142 695.0%   
Total assets Rs m9,13539,113 23.4%  
Interest coverage x43.21,091.0 4.0%   
Debt to equity ratio x00 1,937.9%  
Sales to assets ratio x0.70.8 85.6%   
Return on assets %14.011.4 123.2%  
Return on equity %16.120.8 77.4%  
Return on capital %26.031.9 81.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,066534 948.7%   
Fx outflow Rs m2,0017,091 28.2%   
Net fx Rs m3,065-6,557 -46.7%   
CASH FLOW
From Operations Rs m6993,994 17.5%  
From Investments Rs m-6-1,433 0.4%  
From Financial Activity Rs m-577-3,584 16.1%  
Net Cashflow Rs m116-1,023 -11.4%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 102,036 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 560 Points Lower; Auto and Banking Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 19, 2019 03:35 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - SHASUN PHARMA COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS